Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
aducanumab
affordable care act
alzheimer's disease
biogen
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
clinical trials
deals
detroit blog main
detroit top stories
gilead sciences
indiana blog main
indiana top stories
johnson & johnson
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
nonalcoholic steatohepatitis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
2
×
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
adalimumab (humira)
aduro biotech
aldeyra therapeutics
What
bio
biogen’s
2
×
drug
nash
news
roundup
2
×
aducanumab
alzheimer’s
amyloid
angst
approval
bagged
billions
biogen
biopharmaceutical
brammer
companies
convo
earlier
effects
failure
failures
felt
littered
lost
new
price
remains
ripple
road
strategy
talk
week
Language
Current search:
biogen’s
×
roundup
×
" san francisco top stories "
×
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More